Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gautschi

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2009
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cellsPhillip R Purnell, Philip C Mack, Clifford G Tepper, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2021
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trialPatrizia Froesch, Michael Mark, Sacha I Rothschild, et al.
Cancer Research|April 3, 2008
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancerOliver Gautschi, Clifford G Tepper, Phillip R Purnell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2025
Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II TrialOliver Gautschi, Keunchil Park, Benjamin J Solomon, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2015
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensusFederico Cappuzzo, Denis Moro-Sibilot, Oliver Gautschi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)Thomas Ruhstaller, Miklos Pless, Daniel Dietrich, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2018
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use ProgramSolange Peters, Alessandra Curioni-Fontecedro, Hovav Nechushtan, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2012
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05)Francesco Zappa, Cornelia Droege, Daniel Betticher, et al.
Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2009
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cellsPhillip R Purnell, Philip C Mack, Clifford G Tepper, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2021
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trialPatrizia Froesch, Michael Mark, Sacha I Rothschild, et al.
Cancer Research|April 3, 2008
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancerOliver Gautschi, Clifford G Tepper, Phillip R Purnell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2025
Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II TrialOliver Gautschi, Keunchil Park, Benjamin J Solomon, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2015
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensusFederico Cappuzzo, Denis Moro-Sibilot, Oliver Gautschi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)Thomas Ruhstaller, Miklos Pless, Daniel Dietrich, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2018
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use ProgramSolange Peters, Alessandra Curioni-Fontecedro, Hovav Nechushtan, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2012
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05)Francesco Zappa, Cornelia Droege, Daniel Betticher, et al.
Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.
Pageof 10